Jazz Presents Results of Xywav (Oral Solution) in P-III Withdrawal Study for Adult Patients with Idiopathic Hypersomnia at AAN2021
Shots:
- The P-III withdrawal study involves assessing the efficacy and safety of Xywav (oral solution) vs PBO in a ratio (1:1) in adult patients with idiopathic hypersomnia. The study includes a titration and optimization period of up to 14wks. followed by a 2wks. open-label- SDP
- The study demonstrated a change in ESS score within 2wks.- improvement in PGIc and IHSS. The safety profile was consistent with the known safety profile- and no new safety signals were observed
- The additional data is submitted to the US FDA in the sNDA that was recently accepted for filing and granted Priority Review
Ref: PRNewswire | Image: PRNewswire
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com